Spots Global Cancer Trial Database for m7824
Every month we try and update this database with for m7824 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | NCT04489940 | Triple Negative... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | NCT04246489 | Uterine Cervica... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | NCT03451773 | Cancer of Pancr... Pancreas Cancer Pancreatic Aden... Pancreatic Canc... Pancreatic Neop... | M7824 Gemcitabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | NCT04296942 | Breast Cancer Triple Negative... HER2+ Breast Ca... Hormone Recepto... Metastatic Brea... | Brachyury-TRICO... Entinostat M7824 Ado-trastuzumab... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bioimaging Study of 89Zr-M7824 in NSCLC | NCT04297748 | Non-Small Cell ... | 89Zirconium-M78... M7824 | 18 Years - | Olivia Newton-John Cancer Research Institute | |
| Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection | NCT04247282 | Head and Neck C... Head and Neck N... | M7824 N803 TriAd vaccine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | NCT03833661 | Biliary Tract C... Cholangiocarcin... Gallbladder Can... | M7824 | 18 Years - | EMD Serono | |
| M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | NCT03840915 | Carcinoma, Non-... | Cisplatin Carboplatin Pemetrexed Nab-paclitaxel Gemcitabine Docetaxel M7824 Carboplatin Carboplatin Bintrafusp alfa Paclitaxel | 18 Years - | EMD Serono | |
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | NCT04648826 | Sarcomas Melanomas Germ Cell Tumor... Epithelial Mali... Pulmonary Metas... | AeroEclipse II ... Bintrafusp alfa Azacytidine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | NCT04303117 | Kaposi Sarcoma | NHS-IL12 M7824 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | NCT04574583 | Metastatic Canc... Solid Tumors | SX-682 M7824 MVA-BN-CV301 recombinant fow... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | NCT04432597 | HPV Positive Ca... Vulvar, Vaginal... Anal Cancer Oropharyngeal C... Cervical Cancer | PRGN-2009 (Phas... PRGN-2009 (Phas... M7824 MRI Bone scan CT scan Brain CT Brain MRI Biopsy (Phase I... Biopsy (Phase I... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | NCT04303117 | Kaposi Sarcoma | NHS-IL12 M7824 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | NCT03631706 | Non-small Cell ... | M7824 Pembrolizumab | 18 Years - | EMD Serono | |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | NCT04296942 | Breast Cancer Triple Negative... HER2+ Breast Ca... Hormone Recepto... Metastatic Brea... | Brachyury-TRICO... Entinostat M7824 Ado-trastuzumab... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | NCT04633252 | Cancer Of Prost... Prostate Neopla... | ADT Prednisone M7824 Docetaxel M9241 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | NCT03631706 | Non-small Cell ... | M7824 Pembrolizumab | 18 Years - | EMD Serono | |
| A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer | NCT04349280 | Neoplasms | Bintrafusp alfa | 18 Years - | GlaxoSmithKline | |
| Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) | NCT04551950 | Cervical Cancer | M7824 Carboplatin Paclitaxel Bevacizumab Cisplatin Radiotherapy | 18 Years - | EMD Serono | |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | NCT04066491 | Biliary Tract C... Cholangiocarcin... Gallbladder Can... | M7824 Placebo Gemcitabine Cisplatin | 18 Years - | EMD Serono | |
| Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | NCT04246489 | Uterine Cervica... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | NCT04489940 | Triple Negative... | Bintrafusp alfa | 18 Years - | EMD Serono | |
| M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | NCT03833661 | Biliary Tract C... Cholangiocarcin... Gallbladder Can... | M7824 | 18 Years - | EMD Serono | |
| Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies | NCT04235777 | Urothelial Canc... Bladder Cancer Genitourinary C... Urogenital Neop... Urogenital Canc... | M7824 M9241 Stereotactic bo... | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
